Gastroesophageal reflux disease
Conditions
Sponsors
The Third People's Hospital of Chengdu
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with aged 18-75 years; 2. Patients with typical reflux disease symptoms: heartburn and/or reflux, symptoms lasting more than 3 months, at least twice a week; 3. Patients who voluntarily sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients contraindicated by endoscopy, esophageal pH test and tegoprazan treatment; 2. Patients with warning symptoms, such as unexplained weight loss in the past 3 months, hematemesis, melena or blood in the stool in the past year, progressive dysphagia, anemia or any other symptoms suggestive of suspected malignancy; 3. Patients with any grade of esophageal intraepithelial neoplasia or esophageal cancer, esophageal varices or ulcers, eosinophilic esophagitis or other organic lesions, or hiatal hernia >= 3 cm; 4. Patients with esophageal obstructive lesions (including achalasia and mechanical obstruction) and severe esophageal motility disorders (including distal esophageal spasm, non-contractile esophagus, hypercontractile esophagus); 5. Patients with upper gastrointestinal surgery, such as subtotal gastrectomy, anti-reflux surgery or endoscopic submucosal dissection; 6. Subjects who had taken taken acid suppressors or prokinetic drugs (except antacids) within 7 days before enrollment, and those who refused to discontinue the drugs during the study; 7. Patients taking aspirin and NSAIDs, including COX-2 inhibitors; 8. Patients of lactation or pregnancy; 9. Patients with a history of other serious diseases, such as severe cardiopulmonary disease, renal failure or liver failure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the sensitivity of the Tegoprazan-test;the specificity of the Tegoprazan-test; | — |
Secondary
| Measure | Time frame |
|---|---|
| the sensitivity of the Tegoprazan-test combined with gastro-esophageal reflux disease questionnaire;the sensitivity of the Tegoprazan-test combined with gastro-esophageal reflux disease questionnaire; | — |
Countries
China
Contacts
Public ContactWang Qiong
The Third People's Hospital of Chengdu
Outcome results
None listed